Results 131 to 140 of about 18,546 (173)

Intra-articular Delivery of Recombinant Interleukin-1 Receptor Antagonist Protein (Anakinra) Enhances Graft Function in a Porcine Model of Osteochondral Repair. [PDF]

Am J Sports Med
Stoeckl BD, Flaugh RA, Syed AN, Masada KM, Bernstein ER, Lemmon EA, Jenk AC, Laforest LG, Fogarty NL, Dehghani B, Scanzello CR, Carey JL, Steinberg DR, Mauck RL.   +13 more
europepmc   +1 more source

Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review. [PDF]

Pediatr Rheumatol Online J
Inguscio G, Romano S, Fabi M, Gargiullo L, Marchesi A, Maggio MC, Mastrolia MV, Calabri GB, Simonini G, Giani T.   +9 more
europepmc   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. [PDF]

Arthritis Rheumatol
Eviatar T, Capelusnik D, Campochiaro C, Lacombe V, Jachiet V, Zisapel M, Sagy I, Tayer-Shifman OE, Ozeri D, Kivity S, Tomelleri A, Terrier B, Peleg H, Comont T, Sacre K, Woaye-Hune P, Arnaud L, Lazaro E, Grobost V, Lifermann F, Samson M, Ardois S, Garnier A, Maria A, Cantagrel A, Meyer A, Bouaziz JD, Heiblig M, Dagna L, Diral E, Kosmider O, Elkayam O, Hadjadj J, Georgin-Lavialle S, Fain O, Mekinian A.   +35 more
europepmc   +1 more source

Interleukin-1 receptor antagonist autoantibodies in Still's disease: Mechanistic insights and laboratory testing. [PDF]

World J Methodol
Bouayad A.
europepmc   +1 more source

Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial. [PDF]

Lancet Reg Health Eur
Tavoulareas G, Kontakou-Zoniou O, Antonakos N, Tasouli E, Adamis G, Kakavoulis N, Michelakis E, Skopelitis I, Dakou K, Psarrakis C, Koufargyris P, Astriti M, Sympardi S, Giamarellos-Bourboulis EJ.   +13 more
europepmc   +1 more source

Pericarditis in Patients with Autoimmune Disease: Insights into Prevalence and Optimal Management. [PDF]

Methodist Debakey Cardiovasc J
Fakikh Y, Kazzaz S, Malahfji M.
europepmc   +1 more source

Infliximab-induced lupus with recurrent pericarditis: longitudinal CMR assessment of inflammatory resolution. [PDF]

Int J Cardiovasc Imaging
Mendpara V, El Roumi J, Klein A.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anakinra

BioDrugs, 2002
Anakinra, a recombinant human interleukin-1 (IL-1) receptor antagonist, is the first biological agent approved to block the pro-inflammatory effects of IL-1 in patients with rheumatoid arthritis. In a double-blind, randomised trial in 472 patients with active, severe or very severe rheumatoid arthritis, recipients of subcutaneous anakinra 150 mg/day ...
Risto S, Cvetkovic, Gillian, Keating
openaire   +2 more sources

Anakinra

Reactions Weekly, 2016
George Lazaros, Massimo Imazio, Antonio Brucato, Dimitrios Vassilopoulos, Panagiotis Vasileiou, Marco Gattorno, Dimitrios Tousoulis, Alberto Martini   +7 more
  +6 more sources